# US 2006/0079483 A1 · Heparin oligosaccharides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0079483 A1
- Document ID: US20060079483A1
- Status: Published application
- Kind: A1
- Application number: 11/185,664
- Filed: 2005-07-20
- Published: 2006-04-13
- Earliest claimed: 2004-07-20
- Assignees: Academia Sinica
- Inventors: Shang-Cheng Hung; Jing-Chyi Lee; Xin-An Lu
- Web page: https://patentgrep.com/patent/US20060079483A1

## CPC

- A61K 31/727: Heparin; Heparan
- C07H 3/06: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- C07H 15/04: attached to an oxygen atom of the saccharide radical
- C07H 15/203: Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
- C08B 37/0078: {Degradation products}
- C08L 5/10: Heparin; Derivatives thereof
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present invention provides composition and methods for the synthesis of low molecular weight heparins and heparinoids. The present invention also provides compositions having substantially homogenous populations of desired heparin molecules, or molecules useful in the synthesis of heparin oligosaccharides.

## Claims

### Claim 1

A composition comprising a heparin component, wherein said heparin component is composed of single heparin compounds with the following formula:
wherein n is 1 to 100;
R1 is hydrogen, alkyl, substituted alkyl, saccharide, or substituted saccharide and
R2 is hydrogen, alkyl, substituted alkyl, saccharide, or substituted saccharide; and wherein greater than 60% of said single heparin compounds are the all alpha-isomer.

### Claim 2 (depends on 1)

The composition of claim 1, wherein greater than 70% of said single heparin compounds in said heparin component are the alpha-linked isomer.

### Claim 3 (depends on 1)

The composition of claim 1, wherein greater than 80% of said single heparin compounds in said heparin component are the alpha-linked isomer.

### Claim 4 (depends on 1)

The composition of claim 1, wherein greater than 90% of said single heparin compounds in said heparin component are the alpha-linked isomer.

### Claim 5 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 6 (depends on 5)

The composition of claim 5, wherein said pharmaceutically acceptable carrier is a buffered saline solution.

### Claim 7

A composition comprising a compound component, wherein said compound component is composed of compounds having the following formula:
wherein L is alkoxy or trichloroacetimidate;
P1 is a hydrogen, benzoyl or substituted benzoyl;
P2 is a hydrogen, alkylcarbonyl, or substituted alkylcarbonyl;
P3 is a benzyl or substituted benzyl; and
P4 is hydrogen, 2-naphthylmethyl, substituted 2-naphthylmethyl, p-methoxybenzyloxymethyl, substituted p-methoxybenzyloxymethyl, p-methoxybenzyl, or substituted p-methoxybenzyl.

### Claim 8 (depends on 7)

The composition of claim 7, wherein greater than 55% of said compounds in said compound component are the alpha-linked isomer.

### Claim 9 (depends on 7)

The composition of claim 7, wherein greater than 65% of said compounds in said compound component are the alpha-linked isomer.

### Claim 10 (depends on 7)

The composition of claim 7, wherein greater than 75% of said compounds in said compound component are the alpha-linked isomer.

### Claim 11 (depends on 7)

The composition of claim 7, wherein greater than 85% of said compounds in said compound component are the alpha-linked isomer.

### Claim 12 (depends on 7)

The composition of claim 7, further comprising a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The composition of claim 12, wherein said pharmaceutically acceptable carrier is a buffered saline solution.

### Claim 14

A composition comprising a compound selected from the group consisting of:
